Memorial Hospital Research Laboratories
The Adam Schmitt Lab
Until recently, the vast majority of the noncoding genome was thought be nonfunctional. Thanks to the rapid development of functional genomics, we now know that the noncoding genome is packed with a diverse array of noncoding RNAs and gene regulatory elements. Indeed, it is estimated that more than 80 percent of the genome contains biologically functional sequence, including thousands of long noncoding RNAs.
I am especially interested in how long noncoding RNAs control cellular behavior in response to stressors such as DNA damage and oncogene expression. My laboratory uses a combination of biochemistry, cellular biology, mouse genetics, and functional genomics to identify and characterize long noncoding RNAs involved in these processes.
Schmitt AM*, Shi J*, Wolf AM, Lu CC, King LA, Zou Y. (2006). Wnt-Ryk Signaling Mediates Medial-Lateral Retinotectal Topographic Mapping. Nature. 439 (7072) pp 31-7.
Schmitt AM*, Crawley C*, Kang S, Raleigh D, Yu X, Wahlstrom JS, Voce DJ, Darga TE, Weichselbaum RR, Yamini B. (2011). p50 (NF-kB1) is an effector protein in the cytotoxic response to DNA methylation damage. Molecular Cell. 44 (5) pp 785-96.
Crawley CD, Raleigh DR, Kang S, Voce DJ, Schmitt AM, Weichselbaum RR, Yamini B. (2013). DNA damage-induced cytotoxicity is mediated by the cooperative interaction of phospho-NF-κB p50 and a single nucleotide in the κB-site. Nucleic Acids Research. 41 (2) pp 764-74.
Schmitt AM and Chang HY. (2013). Gene Regulation: Long RNAs wire up cancer growth. Nature. 500 (7464) pp 536-7.
Voce D*, Schmitt AM*, Uppal A*, McNerney M, Wahlstrom J, Bernal G, Nasiri A, Yu X, Crawley C, White K, Weichselbaum RR, Yamini B. NF-kB1 is a haploinsufficient, DNA damage-specific tumor suppressor protein. Oncogene. Advance Online Publication July 24,2014. [*Co-First Authors]
Adam Schmitt, MD
- Physician-scientist Adam Schmitt studies how long noncoding RNAs regulate cellular stress responses and tumor development.
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Adam Schmitt discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.